Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
04 mai 2023 07h30 HE
|
Arbutus Biopharma Corporation
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed...